[Vertebroplasty for chronic back pain due to osteoporotic vertebral compression fractures].

Chronische rugpijn na osteoporotische wervelinzakking.

Journal

Nederlands tijdschrift voor geneeskunde
ISSN: 1876-8784
Titre abrégé: Ned Tijdschr Geneeskd
Pays: Netherlands
ID NLM: 0400770

Informations de publication

Date de publication:
21 Aug 2024
Historique:
medline: 4 9 2024
pubmed: 4 9 2024
entrez: 4 9 2024
Statut: epublish

Résumé

Evidence regarding percutaneous vertebroplasty (PV) for chronic painful osteoporotic vertebral compression fractures (OVCFs) remains limited. To compare pain relief, quality of life, and disability between PV and active control (anesthetic infiltration) interventions for chronic OVCF. Randomized controlled trial. This prospective randomized clinical trial was conducted between May 2013 and June 2019 in participants with pain due to OVCF lasting longer than 3 months with bone marrow edema present at MRI. Study participants were randomly assigned to undergo PV (n = 40) or active control intervention (n = 40). The primary outcome was pain severity, assessed with the visual analog scale (VAS) (range, 0-10) during 12 months after treatment. Secondary outcomes included Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) score (range, 0-100) and Roland Morris Disability Questionnaire (RMDQ) score (range, 0-100). Outcomes were analyzed according to a longitudinal multilevel model used to test the difference between groups in change from baseline across follow-up. The mean age of the 80 participants (54 women) was 69 years ± 10 (SD) in the PV group and 71 years ± 10 in the active control group. VAS score was 7.6 (95% CI: 7.0, 8.2) in the PV group and 7.3 (95% CI: 6.9, 7.8) in the active control group at baseline (P = .47) and 3.9 (95% CI: 3.1, 4.8) and 5.1 (95% CI: 4.3, 6.0), respectively, at month 12 (P = .045). At month 12, the group difference from baseline was 1.3 (95% CI: 0.1, 2.6; P = .02) for VAS, 5.2 (95% CI: 0.9, 9.4; P = .02) for QUALEFFO, and 7.1 (95% CI: -3.3, 17.5; P = .18) for RMDQ, favoring the PV group. In the treatment of pain caused by chronic OVCFs, PV is more effective for pain relief and quality of life improvement than anesthetic injection alone, with similar improvement for disability between the groups.

Identifiants

pubmed: 39228344
pii:

Types de publication

Journal Article Randomized Controlled Trial English Abstract

Langues

dut

Sous-ensembles de citation

IM

Auteurs

Issam Boukrab (I)

Elisabeth-TweeSteden Ziekenhuis, Tilburg.
Contact: i.boukrab@etz.nl.

Alexander Venmans (A)

Elisabeth-TweeSteden Ziekenhuis, Tilburg.

Hans G J Kortman (HGJ)

Elisabeth-TweeSteden Ziekenhuis, Tilburg.

Esther Donga (E)

Elisabeth-TweeSteden Ziekenhuis, Tilburg.

Paul R A M Depauw (PRAM)

Elisabeth-TweeSteden Ziekenhuis, Tilburg.

Paul N M Lohle (PNM)

Elisabeth-TweeSteden Ziekenhuis, Tilburg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH